X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (27) 27
humans (25) 25
index medicus (24) 24
female (23) 23
male (22) 22
aged (21) 21
middle aged (20) 20
adult (15) 15
cancer (15) 15
lung cancer (15) 15
chemotherapy (14) 14
lung neoplasms - drug therapy (14) 14
carcinoma, non-small-cell lung - drug therapy (12) 12
lung cancer, non-small cell (12) 12
care and treatment (11) 11
aged, 80 and over (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
lung neoplasms - pathology (8) 8
research (8) 8
mutation (7) 7
non-small cell lung cancer (7) 7
oncology, experimental (7) 7
patients (7) 7
tumors (7) 7
cancer patients (6) 6
cancer research (6) 6
japan (6) 6
pharmacology & pharmacy (6) 6
trial (6) 6
antineoplastic agents - therapeutic use (5) 5
camptothecin - analogs & derivatives (5) 5
cancer therapies (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
clinical trials (5) 5
combination (5) 5
expression (5) 5
hematology, oncology and palliative medicine (5) 5
lung diseases (5) 5
lung neoplasms - genetics (5) 5
medical research (5) 5
medicine & public health (5) 5
neoplasm staging (5) 5
paclitaxel (5) 5
pharmacology/toxicology (5) 5
protein-tyrosine kinase (5) 5
respiratory system (5) 5
studies (5) 5
survival (5) 5
tyrosine (5) 5
analysis (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
camptothecin - administration & dosage (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
docetaxel (4) 4
epidermal growth factor (4) 4
epidermal growth factor receptors (4) 4
gefitinib (4) 4
hospitals (4) 4
lung cancer, small cell (4) 4
medical colleges (4) 4
metastasis (4) 4
non-small cell lung carcinoma (4) 4
paclitaxel - administration & dosage (4) 4
pharmacology (4) 4
prognosis (4) 4
protein kinase inhibitors - therapeutic use (4) 4
therapy (4) 4
toxicity (4) 4
treatment outcome (4) 4
adenocarcinoma - genetics (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents, phytogenic - administration & dosage (3) 3
biomarkers (3) 3
carcinoma, non-small-cell lung - blood (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, non-small-cell lung - therapy (3) 3
chemoradiotherapy (3) 3
cisplatin (3) 3
cisplatin - administration & dosage (3) 3
clinical medicine (3) 3
college teachers (3) 3
complications and side effects (3) 3
dosage and administration (3) 3
iii trial (3) 3
irinotecan (3) 3
lung neoplasms - mortality (3) 3
lung neoplasms - therapy (3) 3
medicine (3) 3
neoplasms - drug therapy (3) 3
neutropenia (3) 3
nivolumab (3) 3
pharmacokinetics (3) 3
research article (3) 3
respiratory agents (3) 3
respiratory tract diseases (3) 3
statistical analysis (3) 3
surgery (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 671 - 678
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2017, Volume 39, Issue 6, pp. 1146 - 1160
Abstract Purpose Data on the treatment of non–small cell lung cancer (NSCLC) in real-world clinical practice in Japan are limited. This large-scale,... 
Internal Medicine | Medical Education | non–small cell lung cancer | real-world data | Japan | retrospective study | non-small cell lung cancer | POPULATION | COSTS | PHARMACOLOGY & PHARMACY | real world data | Lung Neoplasms - drug therapy | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - therapeutic use | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Databases, Factual | Databases | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | Pharmaceutical industry | Cancer | Chemotherapy | Activities of daily living | Analysis | Medical records | Respiratory tract diseases | Elderly people | Lung cancer | Medical services | Sex | Switches | Oncology | Metastasis | Electronic medical records | Cancer therapies | Data bases | Optimization | Training | Body mass index | Demographics | Platinum | Classification | Diagnosis | Decision trees | Protein-tyrosine kinase | Age | Tyrosine | Medicare | Payment systems | Decision making | Lung diseases | Non-small cell lung carcinoma | Histology | Regression analysis | Patients | Adhesion | Studies | Hospitals | Inhibitors | Body mass | Medical prognosis | Clinical medicine | Mutation | Elderly | Electronic health records | Geriatrics | Smoking | Tumors
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 94, Issue 1, pp. 155 - 162
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2019, Volume 25, Issue 18, pp. 5485 - 5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard... 
CISPLATIN | ONCOLOGY | DOUBLE-BLIND | COMBINATION | PEMETREXED PLUS CARBOPLATIN | EXPRESSION | CHEMOTHERAPY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 10, p. e0223371
Drug-induced interstitial lung disease (DIILD) is a serious side effect of chemotherapy in cancer patients with an extremely high mortality rate. In this... 
Lung Diseases, Interstitial - etiology | Genetic Predisposition to Disease | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Case-Control Studies | Neoplasms - drug therapy | Whole Genome Sequencing | Neoplasms - complications | Lung Diseases, Interstitial - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Biomarkers | Adult | Female | Aged | Polymorphism, Single Nucleotide | Mutation | Chemotherapy | Usage | Lung diseases, Interstitial | Care and treatment | Nucleotide sequencing | DNA sequencing | Cancer | Lung cancer | Risk | Oncology | Genomes | Nucleotides | Kinases | Cancer therapies | Subgroups | Gene sequencing | Homeobox | Proteins | Epidermal growth factor | Genetics | Population | Zinc finger proteins | Growth factors | Protein-tyrosine kinase | Chromosomes | Deoxyribonucleic acid--DNA | Tyrosine | Medical research | Antigens | Epidermal growth factor receptors | Lung diseases | Markers | Health risks | Surfactants | Patients | Zinc | Medicine | Genetic variance | Screening | Genetic markers | Side effects | Hospitals | Pulmonary fibrosis | Chromosome 22 | Replication | Genetic testing | Deoxyribonucleic acid | DNA
Journal Article